1
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, April 7, 1998: US05736137 (387 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


2
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, July 7, 1998: US05776456 (187 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


3
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Burns Doane Swecker & Mathis, December 1, 1998: US05843439 (100 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


4
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma. IDEC Pharmaceutical Corporation, Robin L Teskin, June 4, 2002: US06399061 (86 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


5
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Anti-CD20 antibodies. Biogen Idec, Sidley Austin, September 9, 2008: US07422739 (83 worldwide citation)

Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.


6
Darrell R Anderson, Peter Brams, Nabil Hanna, William S Shestowsky, Cheryl Heard: Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, September 5, 2000: US06113898 (80 worldwide citation)

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal a ...


7
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Robin L Teskin, Pillsbury Winthrop, January 27, 2004: US06682734 (35 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


8
Darrell R Anderson, Peter Brams, Nabil Hanna, William S Shestowsky, Cheryl Heard: Treatment of psoriasis using anti-B7.1 (CD80) antibodies. March 23, 2004: US06709654 (14 worldwide citation)

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal a ...


9
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Expression and use of anti-CD20 Antibodies. Biogen Idec, Sidley Austin, June 29, 2010: US07744877 (11 worldwide citation)

Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.


10
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Expression and use of anti-CD20 antibodies. Biogen Idec, Sidley Austin, June 3, 2008: US07381560 (10 worldwide citation)

Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active ...